Despite no significant correlations were found between serum FABP4 and transaminases, it is worth to note that these molecules may not be reliable markers for the disease, since 75% of patients with NAFLD do not show elevated transaminases levels (Clark et al., 2003). Here, FABP4 is linked to metabolic dysfunction-associated steatotic liver disease.